Andrea Ruberti MD , Laura Sanchis MD, PhD , Andrea Arenas-Loriente MD , Blanca Domenech-Ximenos MD, PhD , Eduardo Flores-Umanzor MD, PhD , Ander Regueiro MD, PhD , Marta Farrero MD, PhD , Marta Sitges MD, PhD , Xavier Freixa MD, PhD , Omar Abdul-Jawad Altisent MD, PhD
{"title":"心内膜炎后原位瓣膜破坏的经皮原位经导管三尖瓣置换术","authors":"Andrea Ruberti MD , Laura Sanchis MD, PhD , Andrea Arenas-Loriente MD , Blanca Domenech-Ximenos MD, PhD , Eduardo Flores-Umanzor MD, PhD , Ander Regueiro MD, PhD , Marta Farrero MD, PhD , Marta Sitges MD, PhD , Xavier Freixa MD, PhD , Omar Abdul-Jawad Altisent MD, PhD","doi":"10.1016/j.jaccas.2025.105280","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Transcatheter tricuspid valve replacement (TTVR) is emerging as an option for treating severe tricuspid regurgitation (TR) in patients at high surgical risk.</div></div><div><h3>Case Summary</h3><div>A 59-year-old man with torrential TR and right heart failure following <em>Staphylococcus aureus</em> tricuspid valve infective endocarditis and extensive leaflet destruction was successfully treated with orthotopic TTVR using the LuX-Valve Plus system (Jenscare), resulting in significant clinical improvement and favorable right ventricular remodeling.</div></div><div><h3>Discussion</h3><div>The LuX-Valve Plus, delivered via transjugular access, enables optimal coaxial alignment during deployment. Its unique features—leaflet graspers, a septal anchoring mechanism, and a flexible frame—provide stability and preserve right ventricular function, making it suitable for complex tricuspid anatomies.</div></div><div><h3>Take-Home Messages</h3><div>Orthotopic TTVR with the LuX-Valve Plus offers a viable option for patients with severe TR and extensive leaflet destruction, previously considered ineligible for surgical or transcatheter repair. Multimodality imaging is essential for procedural planning and optimal outcomes.</div></div>","PeriodicalId":14792,"journal":{"name":"JACC. Case reports","volume":"30 30","pages":"Article 105280"},"PeriodicalIF":0.0000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Percutaneous Orthotopic Transcatheter Tricuspid Valve Replacement for Native Valve Destruction After Endocarditis\",\"authors\":\"Andrea Ruberti MD , Laura Sanchis MD, PhD , Andrea Arenas-Loriente MD , Blanca Domenech-Ximenos MD, PhD , Eduardo Flores-Umanzor MD, PhD , Ander Regueiro MD, PhD , Marta Farrero MD, PhD , Marta Sitges MD, PhD , Xavier Freixa MD, PhD , Omar Abdul-Jawad Altisent MD, PhD\",\"doi\":\"10.1016/j.jaccas.2025.105280\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Transcatheter tricuspid valve replacement (TTVR) is emerging as an option for treating severe tricuspid regurgitation (TR) in patients at high surgical risk.</div></div><div><h3>Case Summary</h3><div>A 59-year-old man with torrential TR and right heart failure following <em>Staphylococcus aureus</em> tricuspid valve infective endocarditis and extensive leaflet destruction was successfully treated with orthotopic TTVR using the LuX-Valve Plus system (Jenscare), resulting in significant clinical improvement and favorable right ventricular remodeling.</div></div><div><h3>Discussion</h3><div>The LuX-Valve Plus, delivered via transjugular access, enables optimal coaxial alignment during deployment. Its unique features—leaflet graspers, a septal anchoring mechanism, and a flexible frame—provide stability and preserve right ventricular function, making it suitable for complex tricuspid anatomies.</div></div><div><h3>Take-Home Messages</h3><div>Orthotopic TTVR with the LuX-Valve Plus offers a viable option for patients with severe TR and extensive leaflet destruction, previously considered ineligible for surgical or transcatheter repair. Multimodality imaging is essential for procedural planning and optimal outcomes.</div></div>\",\"PeriodicalId\":14792,\"journal\":{\"name\":\"JACC. Case reports\",\"volume\":\"30 30\",\"pages\":\"Article 105280\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JACC. Case reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666084925020613\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC. Case reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666084925020613","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Percutaneous Orthotopic Transcatheter Tricuspid Valve Replacement for Native Valve Destruction After Endocarditis
Background
Transcatheter tricuspid valve replacement (TTVR) is emerging as an option for treating severe tricuspid regurgitation (TR) in patients at high surgical risk.
Case Summary
A 59-year-old man with torrential TR and right heart failure following Staphylococcus aureus tricuspid valve infective endocarditis and extensive leaflet destruction was successfully treated with orthotopic TTVR using the LuX-Valve Plus system (Jenscare), resulting in significant clinical improvement and favorable right ventricular remodeling.
Discussion
The LuX-Valve Plus, delivered via transjugular access, enables optimal coaxial alignment during deployment. Its unique features—leaflet graspers, a septal anchoring mechanism, and a flexible frame—provide stability and preserve right ventricular function, making it suitable for complex tricuspid anatomies.
Take-Home Messages
Orthotopic TTVR with the LuX-Valve Plus offers a viable option for patients with severe TR and extensive leaflet destruction, previously considered ineligible for surgical or transcatheter repair. Multimodality imaging is essential for procedural planning and optimal outcomes.